Pharmacogenetics and Individualized Therapy

Pharmacogenetics and Individualized Therapy

Editor(s): Anke-Hilse Maitland-van der Zee, Ann K. Daly

Published Online: 8 AUG 2012 09:40AM EST

Print ISBN: 9780470433546

Online ISBN: 9781118116494

DOI: 10.1002/9781118116494

About this Book

This resource provides thorough coverage of pharmacogenetics and its impact on pharmaceuticals, therapeutics, and clinical practice. It opens with the basics of pharmacogenetics, including drug disposition and pharmacodynamics. The following section moves into specific disease areas, including cardiovascular, psychiatry, cancer, asthma/COPD, adverse drug reactions, transplantation, inflammatory bowel disease, and pain medication. Clinical practice and ethical issues make up the third section, with the fourth devoted to technologies like genotyping, genomics, and proteomics. In the fifth part, chapters discuss the impact of key regulatory issues on the pharmaceutical industry.

Table of contents

    1. You have free access to this content
    1. You have free access to this content
  1. Part I: Pharmacogenetics: Relationship to Pharmacokinetics and Pharmacodynamics

    1. Chapter 4

      Pharmacogenetics of Drug Transporters (pages 101–148)

      Henriette E. Meyer zu Schwabedissen, Markus Grube and Heyo K. Kroemer

  2. Part II: Pharmacogenetics: Therapeutic Areas

    1. Chapter 6

      Cardiovascular Pharmacogenetics (pages 183–213)

      Bas J. M. Peters, Anthonius de Boer, Tom Schalekamp, Olaf H. Klungel and Anke-Hilse Maitland-van der Zee

    2. Chapter 7

      Pharmacogenetics in Psychiatry (pages 215–250)

      Evangelia M. Tsapakis, Sarah Curran, Ruth I. Ohlsen, Nora S. Vyas, Katherine J. Aitchison and Ann K. Daly

    3. Chapter 9

      Pharmacogenetics of Asthma and COPD (pages 271–294)

      Ellen S. Koster, Jan A. M. Raaijmakers, Anke-Hilse Maitland-van der Zee and Gerard H. Koppelman

    4. Chapter 11

      Pharmacogenomics of Inflammatory Bowel Diseases (pages 323–351)

      Alexander Teml, Susanne Karner, Elke Schaeffeler and Matthias Schwab

  3. Part III: Pharmacogenetics: Implementation in Clinical Practice

  4. Part IV: Developments in Pharmacogenetic Research

  5. Part V: Pharmacogenetics: Industry and Regulatory Affairs

  6. Part VI: Conclusions

    1. You have free access to this content